247 - Can We Solve Vaccine Conundrums in Transplant?

Saturday, October 22, 2022

1:45 PM – 3:00 PM US ET

Location: 151 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Steven Pergam, MD, MPH

Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center Associate Professor, University of Washington School of Medicine
Fred Hutchinson Cancer Center
Seattle, WA, United States

Disclosure(s): Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)
Maricar Malinis, MD

Associate Professor of Medicine and Transplant (Surgery), Medical Director of Transplant and Oncology ID
Yale School of Medicine
New Haven, CT, United States

Disclosure(s): Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Faculty(s)

Martina Sester, PhD

Head of Department
Saarland University
Homburg, Germany

Disclosure(s): Astellas Pharma Inc.: Grant/Research Support (Ongoing); Biotest: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Novartis Pharmaceuticals Corp.: Grant/Research Support (Ongoing), Honoraria (Ongoing); Qiagen: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Slides
Natasha Halassa, MD, MPH

Professor
Vanderbilt University

Disclosure(s): Quidel: Donations of kits and viral testing (Terminated), Grant/Research Support (Terminated); Sanofi Pasteur Inc.: donation of vaccines and HAI testing (Terminated), Grant/Research Support (Terminated)

Slides
Deepali Kumar, MD, MSc, FRCPC

Professor of Medicine
University Of Toronto
Toronto, ON, Canada

Disclosure(s): Astellas, Inc: Honoraria (Terminated); Exevir: Advisor/Consultant (Terminated); GSK: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck & Co. Inc: Advisor/Consultant (Terminated); Roche Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Sanofi: Advisor/Consultant (Terminated); Shire/Takeda: Advisor/Consultant (Terminated), Grant/Research Support (Terminated)

Slides

Disclosure(s):

Steven Pergam, MD, MPH: Global Life Technologies, Inc.: Grant/Research Support (Ongoing); Merck and Company, Inc.: Participated in research trial (Terminated)

Maricar F. Malinis, MD: Aicuris: Primary investigator of clinical trial at Yale site, renumeration goes to institution (Ongoing); Takeda: primary investigator of clinical trial at yale site, renumeration goes to institution (Ongoing)

Martina Sester, PhD: Astellas Pharma Inc.: Grant/Research Support (Ongoing); Biotest: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Novartis Pharmaceuticals Corp.: Grant/Research Support (Ongoing), Honoraria (Ongoing); Qiagen: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Natasha Halassa, MD, MPH: Quidel: Donations of kits and viral testing (Terminated), Grant/Research Support (Terminated); Sanofi Pasteur Inc.: donation of vaccines and HAI testing (Terminated), Grant/Research Support (Terminated)

Deepali Kumar, MD, MSc, FRCPC: Astellas, Inc: Honoraria (Terminated); Exevir: Advisor/Consultant (Terminated); GSK: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck & Co. Inc: Advisor/Consultant (Terminated); Roche Inc: Advisor/Consultant (Terminated), Grant/Research Support (Terminated); Sanofi: Advisor/Consultant (Terminated); Shire/Takeda: Advisor/Consultant (Terminated), Grant/Research Support (Terminated)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the principles of immunology that can improve vaccine efficacy in immunocompromised hosts;
recognize available strategies that can improve immune responses in immunocompromised hosts;
identify opportunities that will enhance inclusion of immunocompromised hosts in future vaccine clinical trials

Presentations:

1:45 PM – 2:10 PM US ET

Back to Basics: Understanding Immunology to Improve Vaccine Efficacy in Transplant Patients
Speaker: Martina Sester, PhD – Saarland University
2:10 PM – 2:35 PM US ET

Back to Reality: Optimizing Vaccination Strategies in Transplant Patients
Speaker: Natasha Halassa, MD, MPH – Vanderbilt University
2:35 PM – 3:00 PM US ET

Back to the Future: Advancing Vaccine Development in Immunocompromised Hosts
Speaker: Deepali Kumar, MD, MSc, FRCPC – University Of Toronto